Glenmark Launches Generic Glaucoma Drug

27 Nov 2024 , 12:23 PM

On Wednesday, Glenmark Pharmaceuticals Inc. in the United States announced the launch of Travoprost, an ocular solution used to treat glaucoma.

Using sales statistics from IQVIA for the 12-month period ending in September 2024, the business claimed that Travatan Z ophthalmic solution 0.004% had generated almost USD 66.2 million in sales annually.

According to a statement from the firm, the Travoprost ophthalmic solution (0.004% ionic buffered solution) is both bioequivalent and therapeutically equivalent to the reference listed medication, Travatan Z ophthalmic solution USP, 0.004% of Sandoz, Inc.

Jim Brown, Senior Vice President, Sales & Marketing at Glenmark Pharmaceuticals Inc., stated that the introduction of Travoprost ophthalmic solution USP, 0.004%, expands the company’s line of prescription eye medications.

“This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers,” he stated.

For feedback and suggestions, write to us at [e-mail]